Market Access Pharma’s most expensive question is the last one asked Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.
News White House signs pricing deals with nine more pharmas Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
Market Access The new commercialisation playbook: What BIO 2026 taught eme... BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.
News MFN affecting Swiss medicines access, says Interpharma Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.
Oncology Closing the global evidence gap in oncology, with Flatiron H... Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.